Skip to main content

Table 1 Baseline patient characteristics (N = 153)

From: [18F]FDG-PET/CT in prone compared to supine position for optimal axillary staging and treatment in clinically node-positive breast cancer patients with neoadjuvant systemic therapy

Age, (y) 49 (39–55)
Diagnostic imaging
 Tumor size MRI (mm) 30 (22–47)
 FDG-positive ALNs 2 (1–4)*
Clinical tumor stage
 cT ≤ 1 33 (22%)
 cT2 86 (56%)
 cT ≥ 3 33 (22%)
Clinical axillary stage
 cALN<4 108 (71%)
 cALN≥4 45 (29%)
Histology
 Ductal 136 (89%)
 Lobular 15 (10%)
 Other 2 (1%)
Tumor subtype
 HR+/HER2− 71 (46%)
 HR+/HER2+ 24 (16%)
 HR−/HER2+ 18 (12%)
 Triple-negative 40 (26%)
Grade
 Grade 1 3 (2%)
 Grade 2 77 (53%)
 Grade 3 65 (45%)
 Unknown 7
  1. Data are median (IQR) or N (%)
  2. *The number of FDG-avid nodes was reported as ≥ 10 in 15 patients, in which case the cut-off value of 10 was used
  3. cALN<4 less than four FDG-positive axillary lymph nodes, cALN4 more than four FDG-positive axillary lymph nodes, MARI marking axillary lymph nodes with radioactive iodine seeds, ALNs axillary lymph nodes